AmgenNASDAQ: AMGN

24/7 Wall St. Insights Jefferies is one of Wall Street's fastest-growing firms.

Amgen has been one of the best performing stocks since its IPO in 1983. Over the prior 12 months, the biotech's shares have continued this rich tradition.

Amgen (AMGN) closed at $319.31 in the latest trading session, marking a +0.36% move from the prior day.

The drugmaker has a promising weight-loss drug in clinical trials, MariTide, which could be a game changer. Recent acquisitions have bolstered Amgen's portfolio, which could pave the way for even more growth.

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Biotech stocks operate under a core ethos. While there's been much talk about financially viable sectors – from tech to cryptocurrencies to even precious metals – when you think about it, nothing is more valuable than one's health.

Amgen continues to delight investors with the growth in sales of its key blockbusters and the expansion of its portfolio of medications. In mid-June, Amgen pleased investors by announcing that the FDA had approved Blincyto to treat certain patients with B-precursor acute lymphoblastic leukemia. Ten days earlier, the company released promising results from a Phase 3 clinical trial evaluating Uplizna's efficacy in treating Immunoglobulin G4-related disease.

Amgen's (AMGN) Blincyto is now approved for the treatment of adult and pediatric patients one month and older with Philadelphia chromosome-negative B-ALL in the consolidation phase, regardless of MRD status.

BLINCYTO ® Added to Multiphase Consolidation Chemotherapy Reduced Risk of Death by 58% Showing Superior Overall Survival Versus Chemotherapy Alone First and Only  Bispecific T-cell Engager  (BiTE ® ) Therapy for Consolidation Treatment Regardless of Measurable Residual Disease (MRD) Status THOUSAND OAKS, Calif. , June 14, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of measurable residual disease (MRD) status.